SCHEMBL26779239

SCHEMBL26779239

c1ccc(-c2ccc(N(c3ccc(-c4ccc5c(c4)oc4cc(-c6nc(-c7ccccc7)nc(-c7ccccc7)n6)ccc45)cc3)c3ccc4ccccc4c3)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.40
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 2/20 0.40
TP53 P04637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PGR P06401 1/20 0.35
MAPT P10636 3/20 0.34
HPGD P15428 2/20 0.34
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTGES O14684 1/20 0.34
ALOX5 P09917 1/20 0.34
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33
CYP17A1 P05093 1/20 0.33
CYP19A1 P11511 1/20 0.33
CYP11B1 P15538 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26779230 1.00 MEN1 (0.40) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL25979640 0.99 ALDH1A1 (0.39) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL25979483 0.97 MEN1 (0.40) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL25978941 0.95 ALDH1A1 (0.36) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL25979000 0.95 ALDH1A1 (0.36) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL24255842 0.95 ALDH1A1 (0.38) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL25979759 0.95 CYP1A2 (0.38) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL25979930 0.95 CYP1A2 (0.41) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL25979457 0.95 MEN1 (0.40) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL25979467 0.95 MEN1 (0.41) MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 MEN1 257/4885ALDH1A1 9/4885KMT2A 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.